Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Zogenix, Inc. (ZGNX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
11.85-0.62 (-4.97%)
At close: 04:00PM EST
11.85 0.00 (0.00%)
After hours: 06:03PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close12.47
Open12.45
Bid11.73 x 800
Ask14.66 x 800
Day's Range11.71 - 12.45
52 Week Range11.03 - 23.69
Volume894,950
Avg. Volume556,449
Market Cap681.07M
Beta (5Y Monthly)1.34
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Zogenix To Present New FINTEPLA® (fenfluramine) Data at AES 2021

    Data add to the growing body of evidence supporting the efficacy and safety profile of FINTEPLA for the treatment of Dravet syndromeEMERYVILLE, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it will present new FINTEPLA® (fenfluramine) data from eight abstracts at the American Epilepsy Society (AES) Annual Meeting, taking place from December 3-7, 2021, in Chicago, IL.

  • GlobeNewswire

    Zogenix Announces U.S. FDA Acceptance for Priority Review of Supplemental New Drug Application for FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

    Prescription Drug User Fee Act (PDUFA) Target Action Date of March 25, 2022EMERYVILLE, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies today announced the U.S. Food and Drug Administration (FDA) has accepted for filing and granted Priority Review to the company’s supplemental New Drug Application (sNDA) for the use of FINTEPLA® for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS). The FD

  • GlobeNewswire

    Zogenix Reports Granting of Inducement Awards

    EMERYVILLE, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of directors granted inducement awards to thirteen (13) new non-executive employees. The awards were made on November 15, 2021, under Zogenix’s 2021 Employment Inducement Equity Incentive Award Plan, which was approved by the company’s board of directors under Nasdaq Marketplace Rule 5635(c)(4), for granting equity awards to new employees of Zogenix

Advertisement
Advertisement